Last $59.26 USD
Change Today +0.345 / 0.59%
Volume 1.1M
MRK On Other Exchanges
New York
EN Paris
Sao Paulo
As of 10:24 AM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

merck & co. inc. (MRK) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/1/14 - $59.84
52 Week Low
11/1/13 - $44.62
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MERCK & CO. INC. (MRK)

merck & co. inc. (MRK) Details

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The company’s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of cardiovascular, diabetes and obesity, respiratory, women's health and endocrine, inflammatory and infectious diseases, oncology, ophthalmology, immunology, infectious diseases, and others. This segment also provides vaccines, including preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products comprising vaccines, antibiotics, and anti-inflammatory drugs for respiratory diseases, as well as products for the treatment of fertility disorders. The company’s Consumer Care segment develops, manufactures, and sells over-the-counter products consisting of non-drowsy antihistamines; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant sprays; and products for occasional constipation, frequent heartburn, and overactive bladder in women; foot care products, including topical antifungal, and foot and sneaker odor/wetness products; and sun care products, such as sun care lotions, sprays, and dry oils. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, food chain and mass merchandiser outlets, club stores, and specialty channels, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. It has collaborations with AstraZeneca LP, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi Pasteur S.A., and Sysmex Inostics GmbH. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

77,300 Employees
Last Reported Date: 02/27/14
Founded in 1891

merck & co. inc. (MRK) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.5M
Executive Vice President and President of Mer...
Total Annual Compensation: $1.2M
Executive Vice President and President of Glo...
Total Annual Compensation: $957.3K
Compensation as of Fiscal Year 2013.

merck & co. inc. (MRK) Key Developments

Merck & Co. Inc. Provides Updates on PNEUMOVAX

Merck provided the following statement regarding the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices' (ACIP's) updated pneumococcal vaccine recommendations for adults 65 years of age and older. These recommendations call for a two vaccine regimen utilizing a dose of the pneumococcal conjugate vaccine followed by a dose of Merck's PNEUMOVAX(R) 23, at an interval to be determined by the ACIP, in adults 65 years of age and older who have not previously received pneumococcal vaccine. ACIP also voted that these recommendations for routine use of the pneumococcal conjugate vaccine in adults 65 years of age and older should be reevaluated in 2018 and revised as needed. ACIP will continue to monitor disease trends and the impact of these new recommendations. PNEUMOVAX 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F). PNEUMOVAX 23 (pneumococcal vaccine polyvalent) is approved for use in persons 50 years of age or older and persons aged two years and older who are at increased risk for pneumococcal disease. PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine. Do not administer PNEUMOVAX 23 to individuals with a history of hypersensitivity reaction to any component of the vaccine. According to the National Foundation for Infectious Diseases, approximately 73 million adults in the United States have an indication for pneumococcal vaccination, but have not been vaccinated. It has been estimated that about 59 million working-age (18 to 64 years of age) adults at increased risk for invasive pneumococcal disease remained unvaccinated in 2009. However, vaccination rates have remained low at 20% in this population, according to the CDC's National Health Interview Survey in 2012. This vaccination rate is well below the Healthy People 2020 goals, which call for a pneumococcal disease vaccination rate of 60% for high-risk people between the ages of 18 and 64 years. Moreover, pneumococcal vaccination rates among adults aged 65 years of age or older also remained low at only 59.9% in 2012, versus the Healthy People 2020 target of 90%.

FDA Approves Merck's BELSOMRA (Suvorexant) for the Treatment of Insomnia

Merck announced that the U.S. Food and Drug Administration (FDA) has approved BELSOMRA(R) (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep. BELSOMRA (pronounced bell-SOM-rah) is a highly selective antagonist for orexin receptors. Orexin is a neurotransmitter found in a specific part of the brain that can help keep a person awake. The mechanism by which BELSOMRA exerts its therapeutic effect is presumed to be through antagonism of orexin receptors. In the clinical trials to support efficacy, BELSOMRA was superior to placebo for sleep latency and sleep maintenance as assessed both objectively by polysomnography and subjectively by patient-estimated sleep latency. The recommended dose of BELSOMRA is 10 mg, taken no more than once per night and within 30 minutes of going to bed, with at least 7 hours remaining before the planned time of awakening. The total dose should not exceed 20 mg once daily. The FDA has recommended BELSOMRA be classified by the U.S. Drug Enforcement Administration (DEA) as a scheduled product. Earlier this year, the DEA proposed a Schedule IV drug classification under the Controlled Substances Act. The DEA has not yet issued a final decision on the scheduling for BELSOMRA and therefore product cannot become available before that decision. BELSOMRA (suvorexant) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Select safety information about BELSOMRA: BELSOMRA is contraindicated in patients with narcolepsy. BELSOMRA can impair daytime wakefulness. Central nervous system (CNS) depressant effects can last for up to several days after discontinuation. BELSOMRA can impair driving skills and may increase the risk of falling asleep while driving. Co-administration with other CNS depressants (benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. Patients should be advised not to consume alcohol in combination with BELSOMRA because of additive effects. Dosage adjustments of BELSOMRA and of concomitant CNS depressants may be necessary when administered together because of potentially additive effects. The use of BELSOMRA with other drugs to treat insomnia is not recommended. The risk of next-day impairment, including impaired driving, is increased if BELSOMRA is taken with less than a full night of sleep remaining, if a higher than the recommended dose is taken, if co-administered with other CNS depressants, or if co-administered with other drugs that increase blood levels of BELSOMRA. Patients should be cautioned against driving and other activities requiring complete mental alertness if taken in these circumstances. Reevaluate patients for co-morbid conditions if insomnia persists after 7 to 10 days of treatments. A variety of cognitive and behavioral changes have been reported to occur in association with the use of hypnotics such as BELSOMRA. 'Sleep driving' and other complex behaviors, with amnesia for the event have been reported with the use of hypnotics. These events can occur in hypnotic-naïve as well as in hypnotic-experienced persons. The use of alcohol and other CNS depressants may increase the risk of such behaviors. Discontinuation of BELSOMRA should be strongly considered for patients who report any complex sleep behavior. In clinical studies, a dose-dependent increase in suicidal ideation was observed in patients taking BELSOMRA, as assessed by questionnaire. Immediately evaluate patients with suicidal ideation or any new onset behavioral changes. Worsening depression or suicidal thinking, thoughts and actions have been reported with the use of sedative-hypnotics. Suicidal tendencies may be present in such patients and protective measures may be required. Intentional overdose is more common in this group of patients; therefore, the lowest number of tablets that is feasible should be prescribed for the patient at any one time. The effect of BELSOMRA on respiratory function should be considered. The risk of sleep paralysis, hypnagogic/hypnopompic hallucinations and cataplexy-like symptoms increases with increasing doses of BELSOMRA. BELSOMRA is not recommended for patients with severe hepatic impairment or those taking a strong CYP3A inhibitor. In clinical studies the most common adverse reaction (reported in 5% or more of patients treated with 15 or 20 mg of BELSOMRA and at least twice the placebo rate) was somnolence (BELSOMRA 7%; placebo 3%). The recommended dose of BELSOMRA is 5 mg in patients receiving moderate CYP3A inhibitors. Digoxin levels should be monitored closely as slight increases were seen with co-administration of BELSOMRA. BELSOMRA availability: BELSOMRA is expected to be available in late 2014 or early 2015.

KYORIN Pharmaceutical Co., Ltd. Enters into License Agreement with Merck & Co., Inc for OAB Therapeutic Agent

KYORIN Pharmaceutical Co. Ltd. has entered into a license agreement with Merck & Co. Inc. for Merck's investigational overactive bladder, or OAB, therapeutic agent, Vibegron. Under the terms of the agreement, Merck has granted to Kyorin a license to develop, manufacture and commercialize Vibegron in Japan. Kyorin will make an upfront payment and additional contingent milestone payments to Merck, including royalties on product sales. Vibegron is a new chemical entity discovered by Merck with selective beta 3 adrenergic receptor agonist activity and is expected to be a once daily therapeutic medication in patients with OAB. Vibegron improves OAB symptoms such as urinary urgency, micturition and urge incontinence through stimulation of the beta 3 receptor in bladder which improves bladder muscle atony during the period of urine pooling. Multi-national Ph2b studies including Japan have been completed by Merck, and Kyorin is planning to proceed development in a Phase III study in Japan.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK:US $59.27 USD +0.36

MRK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €98.57 EUR -0.82
Gilead Sciences Inc $102.20 USD +0.92
GlaxoSmithKline PLC 1,416 GBp +3.50
Pfizer Inc $28.88 USD -0.0633
Sanofi €79.13 EUR -0.62
View Industry Companies

Industry Analysis


Industry Average

Valuation MRK Industry Range
Price/Earnings 31.1x
Price/Sales 3.9x
Price/Book 3.5x
Price/Cash Flow 30.3x
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at